Wide spectrum of tumors in knock-in mice carrying a Cdk4 protein insensitive to INK4 inhibitors

AUTOR(ES)

Sotillo, Rocío

FONTE

Oxford University Press

RESUMO

We have introduced a point mutation in the first coding exon of the locus encoding the cyclin-dependent kinase 4 (Cdk4) by homologous recombination in embryonic stem cells. This mutation (replacement of Arg24 by Cys) was first found in patients with hereditary melanoma and renders Cdk4 insensitive to INK4 inhibitors. Here, we report that primary embryonic fibroblasts expressing the mutant Cdk4R24C kinase are immortal and susceptible to transformation by Ras oncogenes. Moreover, homozygous Cdk4R24C/R24C mutant mice develop multiple tumors with almost complete penetrance. The most common neoplasia (endocrine tumors and hemangiosarcomas) are similar to those found in pRb+/– and p53–/– mice. This Cdk4 mutation cooperates with p53 and p27Kip1 deficiencies in decreasing tumor latency and favoring development of specific tumor types. These results provide experimental evidence for a central role of Cdk4 regulation in cancer and provide a valuable model for testing the potential anti-tumor effect of Cdk4 inhibitors in vivo.

Documentos Relacionados

• Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6.
• Pax3-FKHR Knock-In Mice Show Developmental Aberrations but Do Not Develop Tumors
• Structural basis of inhibition of CDK–cyclin complexes by INK4 inhibitors
• Knock-In Mouse Models of Huntington's Disease
• Altered RNA splicing contributes to skeletal muscle pathology in Kennedy disease knock-in mice